These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 14725299)

  • 1. France critiques its incubator before refinancing.
    Louët S
    Nat Biotechnol; 2004 Jan; 22(1):126. PubMed ID: 14725299
    [No Abstract]   [Full Text] [Related]  

  • 2. Biotechnology venture capital booms in Japan.
    Saegusa A
    Nat Biotechnol; 2000 Mar; 18(3):256. PubMed ID: 10700128
    [No Abstract]   [Full Text] [Related]  

  • 3. Financing bonanza set to continue.
    Davidson S
    Nat Biotechnol; 2000 Sep; 18(9):922-3. PubMed ID: 10973203
    [No Abstract]   [Full Text] [Related]  

  • 4. France boosts funding for biotechnology start-ups.
    Goodman S
    Nature; 2001 Dec; 414(6864):573. PubMed ID: 11740520
    [No Abstract]   [Full Text] [Related]  

  • 5. Putting a price on biotechnology.
    Stewart JJ; Allison PN; Johnson RS
    Nat Biotechnol; 2001 Sep; 19(9):813-7. PubMed ID: 11533634
    [No Abstract]   [Full Text] [Related]  

  • 6. Fickle financing climate continues.
    Mitchell P
    Nat Biotechnol; 2001 Aug; 19(8):695-6. PubMed ID: 11479542
    [No Abstract]   [Full Text] [Related]  

  • 7. Biotech marks time in Q3.
    Lawrence S
    Nat Biotechnol; 2005 Nov; 23(11):1332. PubMed ID: 16273049
    [No Abstract]   [Full Text] [Related]  

  • 8. The changing attitude of European VCs.
    Mitchell P
    Nat Biotechnol; 2004 Apr; 22(4):479. PubMed ID: 15085807
    [No Abstract]   [Full Text] [Related]  

  • 9. New Zealand launches biotech seed fund.
    Griggs K
    Nat Biotechnol; 2004 Apr; 22(4):480-1. PubMed ID: 15085809
    [No Abstract]   [Full Text] [Related]  

  • 10. Sumitomo buys Oxford finance.
    Bouchie A
    Nat Biotechnol; 2004 Apr; 22(4):480. PubMed ID: 15085808
    [No Abstract]   [Full Text] [Related]  

  • 11. Are small biotechs still underselling themselves?
    Ransom J
    Nat Biotechnol; 2006 May; 24(5):477. PubMed ID: 16680112
    [No Abstract]   [Full Text] [Related]  

  • 12. Gold in the ivory tower: equity rewards of outlicensing.
    Edwards M; Murray F; Yu R
    Nat Biotechnol; 2006 May; 24(5):509-15. PubMed ID: 16680129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kiran Mazumdar-Shaw.
    Jayaraman KS
    Nat Biotechnol; 2005 Jan; 23(1):11. PubMed ID: 15637602
    [No Abstract]   [Full Text] [Related]  

  • 14. IPO floodgates unlikely to open after Ark floatation.
    Louët S
    Nat Biotechnol; 2004 Apr; 22(4):367-8. PubMed ID: 15060538
    [No Abstract]   [Full Text] [Related]  

  • 15. Biotechnology financing dilemmas and the role of special purpose entities.
    Schiff L; Murray F
    Nat Biotechnol; 2004 Mar; 22(3):271-7. PubMed ID: 14990945
    [No Abstract]   [Full Text] [Related]  

  • 16. Life support for life science innovation?
    Nat Biotechnol; 2007 Feb; 25(2):144. PubMed ID: 17287731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biotech finance: a family affair.
    Hurwitz EM
    Nat Biotechnol; 1999 Feb; 17 Suppl():BE35-7. PubMed ID: 10052326
    [No Abstract]   [Full Text] [Related]  

  • 18. At ground level.
    Bertschinger J
    Nat Biotechnol; 2010 Aug; 28(8):775-7. PubMed ID: 20722095
    [No Abstract]   [Full Text] [Related]  

  • 19. Valuing biotechnology assets.
    Nelson TR; Mukherji A
    Nat Biotechnol; 1998 Jun; 16(6):525-9. PubMed ID: 9624681
    [No Abstract]   [Full Text] [Related]  

  • 20. The rise of venture capital and biotechnology in the US and Europe.
    Lee DP; Dibner MD
    Nat Biotechnol; 2005 Jun; 23(6):672-6. PubMed ID: 15940233
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.